1. Home
  2. ZCMD vs MBIO Comparison

ZCMD vs MBIO Comparison

Compare ZCMD & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zhongchao Inc.

ZCMD

Zhongchao Inc.

N/A

Current Price

$1.78

Market Cap

6.9M

Sector

Real Estate

ML Signal

N/A

MBIO

Mustang Bio Inc.

HOLD

Current Price

$0.71

Market Cap

6.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZCMD
MBIO
Founded
2012
2015
Country
China
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.9M
6.2M
IPO Year
2019
2023

Fundamental Metrics

Financial Performance
Metric
ZCMD
MBIO
Price
$1.78
$0.71
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
34.8K
29.6K
Earning Date
04-28-2026
03-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
98.99
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.18
$0.53
52 Week High
$1.95
$7.00

Technical Indicators

Market Signals
Indicator
ZCMD
MBIO
Relative Strength Index (RSI) 68.14 28.85
Support Level $1.02 $0.53
Resistance Level $1.94 $1.00
Average True Range (ATR) 0.18 0.06
MACD -0.04 -0.02
Stochastic Oscillator 77.23 9.18

Price Performance

Historical Comparison
ZCMD
MBIO

About ZCMD Zhongchao Inc.

ZHONGCHAO Inc is an offshore holding company incorporated in the Cayman Islands. Through its subsidiaries, it is a platform-based internet technology company offering services to patients with oncology and other diseases in China. It provide the healthcare information, education, and training services to the healthcare professionals under their MDMOOC brand. It also provide focused patient management services, through Zhongxun IT system and WeChat mini program and Zhongxin Health WeChat mini program, to pharmaceutical enterprises and NFP customers.

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Share on Social Networks: